share_log

Regeneron Pharmaceuticals | 8-K: Regeneron Reports Third Quarter 2024 Financial and Operating Results

Regeneron Pharmaceuticals | 8-K: Regeneron Reports Third Quarter 2024 Financial and Operating Results

再生元制药公司 | 8-K：Regeneron 公布2024年第三季度财务和经营业绩
美股SEC公告 ·  2024/10/31 07:15

Moomoo AI 已提取核心信息

Regeneron reported strong Q3 2024 results with total revenue up 11% to $3.72 billion. Dupixent global net sales surged 23% to $3.82 billion, while U.S. EYLEA HD and EYLEA sales rose 3% to $1.54 billion. Libtayo global net sales increased 24% to $289 million.GAAP diluted EPS grew 30% to $11.54, and non-GAAP diluted EPS rose 8% to $12.46. The quarter included a $0.43 impact from an acquired IPR&D charge. R&D expenses increased 18% to $1.27 billion as the company advanced its clinical pipeline, including late-stage oncology programs.Regeneron achieved significant milestones, including FDA approval of Dupixent for COPD and positive results in chronic spontaneous urticaria and bullous pemphigoid trials. The company maintains a strong financial position with $18.3 billion in cash and marketable securities as of September 30, 2024.
Regeneron reported strong Q3 2024 results with total revenue up 11% to $3.72 billion. Dupixent global net sales surged 23% to $3.82 billion, while U.S. EYLEA HD and EYLEA sales rose 3% to $1.54 billion. Libtayo global net sales increased 24% to $289 million.GAAP diluted EPS grew 30% to $11.54, and non-GAAP diluted EPS rose 8% to $12.46. The quarter included a $0.43 impact from an acquired IPR&D charge. R&D expenses increased 18% to $1.27 billion as the company advanced its clinical pipeline, including late-stage oncology programs.Regeneron achieved significant milestones, including FDA approval of Dupixent for COPD and positive results in chronic spontaneous urticaria and bullous pemphigoid trials. The company maintains a strong financial position with $18.3 billion in cash and marketable securities as of September 30, 2024.
再生元公司发布了2024年第三季度的强劲业绩，总营业收入增长11%，达到37.2亿美金。Dupixent的全球净销售额激增23%，达到38.2亿美金，而美国的EYLEA HD和EYLEA的销售额上涨3%，达到15.4亿美金。Libtayo的全球净销售额增加24%，达到28900万美金。根据GAAP摊薄后每股收益增长30%，为11.54美金，非GAAP摊薄后每股收益增长8%，为12.46美金。本季度因收购的知识产权和研发费用影响了0.43美金。研发费用增长18%，达到12.7亿美金，因为公司推进其临床管道，包括晚期肿瘤项目。再生元公司取得了重要里程碑，包括Dupixent在慢性阻塞性肺病（COPD）获FDA批准，以及在慢性自发性荨麻疹和大疱性类天疱疮试验中的积极结果。到2024年9月30日，公司保持强劲的财务状况，现金和可交易证券达到183亿美金。
再生元公司发布了2024年第三季度的强劲业绩，总营业收入增长11%，达到37.2亿美金。Dupixent的全球净销售额激增23%，达到38.2亿美金，而美国的EYLEA HD和EYLEA的销售额上涨3%，达到15.4亿美金。Libtayo的全球净销售额增加24%，达到28900万美金。根据GAAP摊薄后每股收益增长30%，为11.54美金，非GAAP摊薄后每股收益增长8%，为12.46美金。本季度因收购的知识产权和研发费用影响了0.43美金。研发费用增长18%，达到12.7亿美金，因为公司推进其临床管道，包括晚期肿瘤项目。再生元公司取得了重要里程碑，包括Dupixent在慢性阻塞性肺病（COPD）获FDA批准，以及在慢性自发性荨麻疹和大疱性类天疱疮试验中的积极结果。到2024年9月30日，公司保持强劲的财务状况，现金和可交易证券达到183亿美金。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间